So, here's a biotech story with all the classic ingredients: a stock that doubles in a day, an FDA nod that sounds fancy, and a Phase 3 trial that just got stopped. Immutep Limited (IMMP), a clinical-stage biotech working on cancer and autoimmune therapies, saw its shares jump about 100% on Wednesday. The trigger? The FDA gave its lead drug, eftilagimod alfa, an orphan drug designation for treating soft tissue sarcoma.
An orphan designation is basically the FDA's way of saying, "Hey, this disease is rare, and we want to encourage companies to develop treatments for it." It comes with perks like regulatory support and potential market exclusivity. For Immutep, which focuses on therapies targeting Lymphocyte Activation Gene-3 (LAG-3) to tweak immune responses, it's a nice boost for its oncology ambitions.
But, and there's always a but in biotech, let's rewind a bit. Back in March, Immutep halted its TACTI-004 Phase 3 trial. This was a big study looking at eftilagimod alfa combined with Merck & Co. Inc.'s (MRK) Keytruda and chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC). The company called it an "orderly wind-down" after reviewing safety and efficacy data, and it's now reassessing where to put its money. Not exactly a disaster, but not a green light either.
Efti, as the drug is nicknamed, isn't just a one-trick pony. It's being tested for a bunch of solid tumors—NSCLC, head and neck squamous cell carcinoma, soft tissue sarcoma, and breast cancer. In May 2025, Immutep shared more data from another trial, INSIGHT-003, which combined efti with Keytruda and chemo in front-line NSCLC. So, the science keeps chugging along, even if one path hit a detour.
Over in autoimmune land, Immutep has IMP761, a first-in-class LAG-3 agonist antibody. In December 2025, an update from a Phase I study in healthy folks showed it was well-tolerated at doses of 2.5 and 7 mg/kg, with no serious side effects. Early days, but it adds another layer to the story.
Now, what do the pros think? The stock has an average Buy rating with a price target of $5.50, which sounds optimistic given the recent volatility. But dig a little deeper, and you'll see some skepticism. In March, Citizens downgraded it to Market Perform, and Baird moved to Neutral, slashing its target to $1.00. So, while some are cheering, others are tapping the brakes.
As of Wednesday, Immutep shares were up 97.24% at $1.02. A wild ride, sure, but it shows how a single regulatory nod can light a fire under a stock, even when the broader picture has its share of question marks. For investors, it's a reminder that in biotech, good news and bad news often travel together.
